Trial Profile

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metablok-Arch Biopartners (Primary)
Indications Acute kidney injury; Acute lung injury; Blood coagulation disorders; COVID 2019 infections; Inflammation; Respiratory insufficiency; SARS-CoV-2 acute respiratory disease
Focus Proof of concept; Therapeutic Use
Sponsors Arch Biopartners

18 Mar 2024 According to an Arch Biopartners Media release, data from this study was published in British Medical Journal Open (BMJ Open).
18 Mar 2024 Results presented in an Arch Biopartners Media Release.
01 Dec 2021 Status changed from active, no longer recruiting to completed, according to an Arch Biopartners media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com